Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Georgina V. Long(Westmead Hospital), Razelle Kurzrock(The University of Texas MD Anderson Cancer Center), Kevin B. Kim(The University of Texas MD Anderson Cancer Center), Tobias Arkenau(GlaxoSmithKline (Australia)), Michael P. Brown(The University of Adelaide), Omid Hamid(Angeles Clinic and Research Institute), Jeffrey R. Infante(Sarah Cannon), Michael Millward(The University of Western Australia), Anna C. Pavlick(New York University), Steven O’Day(Angeles Clinic and Research Institute), Samuel C. Blackman(GlaxoSmithKline (United States)), C. Martin Curtis(GlaxoSmithKline (United States)), Peter F. Lebowitz(GlaxoSmithKline (United States)), Bo Ma(GlaxoSmithKline (United States)), Danièle Ouellet(GlaxoSmithKline (United States)), Richard Kefford(Westmead Hospital)
The Lancet
May 1, 2012
10.1016/s0140-6736(12)60398-5
Cited by 933Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis